We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+3.32%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.3B
AUM Growth
+$177M
Cap. Flow
+$235M
Cap. Flow %
18.05%
Top 10 Hldgs %
40.67%
Holding
213
New
103
Increased
34
Reduced
21
Closed
43

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$47.9M
2
ABBV icon
AbbVie
ABBV
+$27.8M
3
JNJ icon
Johnson & Johnson
JNJ
+$18.7M
4
LPSN icon
LivePerson
LPSN
+$16.1M
5
AZN icon
AstraZeneca
AZN
+$13.6M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$40.5M
2
BMY icon
Bristol-Myers Squibb
BMY
+$26.4M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$12.8M
4
ZYME icon
Zymeworks
ZYME
+$11.6M
5
META icon
Meta Platforms (Facebook)
META
+$10.9M

Sector Composition

Rank Sector Weight
1 Healthcare 62.55%
2 Technology 7.69%
3 Industrials 4.91%
4 Financials 2.93%
5 Consumer Discretionary 1.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BTAI icon
176
BioXcel Therapeutics
BTAI
$24.9M
– –
-1,756
Closed -$1.3M
BURL icon
177
Burlington
BURL
$23.2B
– –
-35,000
Closed -$9.15M
BYSI icon
178
BeyondSpring
BYSI
$47.3M
– –
-598,000
Closed -$7.3M
CLRB icon
179
Cellectar Biosciences
CLRB
$20.5M
– –
-292
Closed -$182K
ETNB
180
DELISTED
89bio
ETNB
– –
-69,939
Closed -$1.7M
FOLD
181
DELISTED
Amicus Therapeutics
FOLD
– –
-265,753
Closed -$6.14M
FROG icon
182
JFrog
FROG
$9.66B
– –
-72,377
Closed -$4.55M
IMTX icon
183
Immatics
IMTX
$1.18B
– –
-823,391
Closed -$8.88M
IOVA icon
184
Iovance Biotherapeutics
IOVA
$1.82B
– –
-127,289
Closed -$5.91M
KRON
185
DELISTED
Kronos Bio
KRON
– –
-35,000
Closed -$1.04M
KRYS icon
186
Krystal Biotech
KRYS
$10.1B
– –
-101,044
Closed -$6.06M
CYPH
187
Cypherpunk Technologies Inc
CYPH
$62.9M
– –
-80,000
Closed -$1.8M
META icon
188
Meta Platforms (Facebook)
META
$1.42T
– –
-39,998
Closed -$10.9M
MRK icon
189
CALL
Merck
MRK
$322B
– –
-136,240
Closed -$10.6M
NVS icon
190
CALL
Novartis
NVS
$297B
– –
-120,000
Closed -$11.3M
NVS icon
191
Novartis
NVS
$297B
– –
-429,000
Closed -$40.5M
OLMA icon
192
Olema Pharmaceuticals
OLMA
$1B
– –
-15,200
Closed -$731K
PRAX icon
193
Praxis Precision Medicines
PRAX
$8.58B
– –
-6,667
Closed -$5.5M
QURE icon
194
uniQure
QURE
$3.03B
– –
-216,000
Closed -$7.8M
RCKT icon
195
Rocket Pharmaceuticals
RCKT
$340M
– –
-75,000
Closed -$4.11M
SAGE
196
DELISTED
Sage Therapeutics
SAGE
– –
-8,554
Closed -$740K
SRPT icon
197
CALL
Sarepta Therapeutics
SRPT
$1.57B
– –
-370,000
Closed -$63.1M
SRPT icon
198
Sarepta Therapeutics
SRPT
$1.57B
– –
-75,000
Closed -$12.8M
SRPT icon
199
PUT
Sarepta Therapeutics
SRPT
$1.57B
– –
-75,000
Closed -$12.8M
VRDN icon
200
Viridian Therapeutics
VRDN
$2.09B
– –
-30,497
Closed -$502K
5 6 7
8
9

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2021 Portfolio in Review

As of Q1 2021, Sphera Funds Management held 213 positions worth $1.3B, up 16% from $1.13B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Sphera Funds Management deployed $235M of net new capital in Q1 2021, opening 103 new positions and adding to 34 existing holdings. Its largest new stake was Sanofi: 997,900 shares worth $49.4M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 68% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $26.4M trimmed.

  • Sphera Funds Management's largest Q1 2021 buy was Sanofi: 997,900 shares worth $49.4M.
  • Sphera Funds Management added most to AbbVie in Q1 2021, an estimated $27.8M increase.
  • Sphera Funds Management's biggest Q1 2021 reduction was Bristol-Myers Squibb, cutting an estimated $26.4M.
  • Sphera Funds Management fully exited Novartis in Q1 2021, selling an estimated $40.5M.
  • Sphera Funds Management's ten largest holdings make up 41% of its $1.3B portfolio in Q1 2021.
  • Sphera Funds Management opened 103 new positions and closed 43 in Q1 2021.
  • Sphera Funds Management's portfolio value rose 16% quarter-over-quarter to $1.3B.

Based on Sphera Funds Management's 13F filing for Q1 2021, filed 17 May 2021.